Abstract

BackgroundCosibelimab is a high affinity, fully-human IgG1 monoclonal antibody that directly binds to programmed death ligand-1 (PD-L1) and blocks its interaction with the programmed death receptor-1 (PD-1) and B7.1 receptors...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma
Sophia Z Shalhout ... David M Miller
Journal of the American Academy of Dermatology | VOL. 85
Sophia Z Shalhout, et. al.Sophia Z Shalhout ... David M Miller
19 Jan 2021
Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?
Jordi Remon ... Benjamin Besse
Journal of Thoracic Oncology | VOL. 14
Jordi Remon, et. al.Jordi Remon ... Benjamin Besse
23 Apr 2019
Abstract LB040: Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study
...
American Journal of Cancer | VOL. 81
, et. al. ...
01 Jul 2021
Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.
Bob T Li ...
Journal of Clinical Oncology | VOL. 40
Bob T Li, et. al.Bob T Li ...
01 Jun 2022
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
EphA3 CAR T cells are effective against glioblastoma in preclinical models
Paulo Martins ... Rajiv Khanna
Journal for Immunotherapy of Cancer | VOL. 12
Paulo Martins, et. al.Paulo Martins ... Rajiv Khanna
07 Aug 2024
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses
Leesa Lertsumitkul ... Misty R Jenkins
Journal for Immunotherapy of Cancer | VOL. 12
Leesa Lertsumitkul, et. al.Leesa Lertsumitkul ... Misty R Jenkins
07 Aug 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Michael Schenker ... Massimo Di Nicola
Journal for Immunotherapy of Cancer | VOL. 12
Michael Schenker, et. al.Michael Schenker ... Massimo Di Nicola
06 Aug 2024
Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer
Zixiang Wang ... Baoxia Cui
Journal for Immunotherapy of Cancer | VOL. 12
Zixiang Wang, et. al.Zixiang Wang ... Baoxia Cui
06 Aug 2024
View more papers